Navigation Links
Naurex Initiates Phase II Clinical Trial of Novel Antidepressant GLYX-13 in Treatment-Resistant Depression
Date:6/22/2011

here is a high unmet need for faster, more effective and safe antidepressants to help the millions of patients poorly served by current agents.  We look forward to reporting the results of this first assessment of the potential efficacy of GLYX-13 in patients with treatment-resistant depression during 2012."

In preclinical studies, GLYX-13 has demonstrated the robust antidepressant-like activity of ketamine, including its rapid onset and long duration of effect, with no signs of side effects.  It also achieved the widest therapeutic ratio between efficacy and side effects (>500:1) of any known NMDAR modulator.  

In a Phase I trial, GLYX-13 was well tolerated, with adverse events for the groups receiving GLYX-13 and placebo all rated as mild.  There were no signs of the schizophrenia-like side effects associated with other drugs that modulate the NMDAR.

For more information about the GLYX-13 Phase II trial, see http://clinicaltrials.gov/ct2/show/NCT01234558?term=glyx-13&rank=2.

About NaurexNaurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor in a safe way -- Glycine-site Functional Partial Agonists (GFPAs).  In preclinical studies, Naurex's lead product, GLYX-13, has shown promising signs of rapid-acting, long-lasting antidepressant activity with excellent safety, and the safety results have been confirmed in a Phase I clinical trial.  Naurex is currently conducting a Phase II trial to assess GLYX-13 in patients who have had an inadequate response to an existing antidepressant treatment.  Naurex's second-generation program, which comprises novel patented GFPA chemistry classes with key molecular features, represents a platform for the development of new therapies for a va
'/>"/>

SOURCE Naurex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Naurex Inc. Initiates Phase I Clinical Trial of its Novel Mechanism NMDA Modulator GLYX-13 in Treatment-Resistant Depression
2. Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects
3. Cebix Initiates Phase 1b Clinical Trial with Drug Candidate Ersatta™
4. American Regent Initiates Voluntary Nationwide Recall of Concentrated Sodium Chloride Injection, USP, 23.4%, 30 mL Single Dose Vial Due to Particulates
5. Sangart Initiates Phase 2b Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock
6. Masimo Initiates Limited Market Release of E1, Single-Patient-Use Ear Sensor for Pulse Oximetry Monitoring
7. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
8. American Regent Initiates Nationwide Voluntary Recall of Sterile Water for Injection, USP, 50 mL Single Dose Vial Due to Particulate Matter
9. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
10. BAETA Corp Initiates Clinical Trial at NYU School of Medicine to Measure Efficacy of Pain Recording Device
11. Vista Partners Initiates Coverage on Helix BioPharma Corporation; Target Price $6.20
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... , July 13, 2014 ... in Tokio veranstalteten ... firmenseitigen Bemühungen zur Neuausrichtung seines Forschungsrahmenprogramms. Die ... Überblick über die fortgeschrittenen klinischen Programme und ... Ziel der Tagung bestand darin, aktuelle Meldungen ...
(Date:7/13/2014)... 13, 2014  Eli Lilly and Company (NYSE: ... its non-clinical study in genetically engineered mice examining ... beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). ... effective in removing clumps of amyloid-beta protein in ... to lead to Alzheimer,s disease (AD) – than ...
(Date:7/11/2014)... LOS ANGELES , July 11, 2014 /PRNewswire-iReach/ ... of e-liquid, a vegetable-glycol solution for use in ... one of the active ingredients in cannabis, cannabidiol ... in personal vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... Oct. 12 "The FDA,s just approved monthly drug treatment ... largest substance abuse treatment provider, CRC Health Group, Recovery Division ... country. Rhodes said the new treatment regimen "will provide addicts ... a new way to reduce or eliminate relapse. We are ...
... (NYSE: WPI ), a leading specialty pharmaceutical company, ... quarter 2010 financial results on Thursday, November 4, 2010 prior ... will also host a conference call and webcast at 8:30 ... its financial results and provide an update on the Company,s ...
Cached Medicine Technology:FDA's Just Approved Monthly Drug Treatment, Vivitrol Could Be 'Game Changer,' Says Country's Largest Drug Treatment Recovery President, CRC's Jerry Rhodes; Provides Addicts 'One Decision A Month Instead of 30' 2Watson to Host Conference Call and Webcast to Discuss Third Quarter 2010 Earnings 2
(Date:7/13/2014)... 13, 2014 Advanced boilers are ... least amount of fossil fuels, produce high-capacity power, ... to increased global warming and climate change concerns, ... reduce harmful gas emissions and pollutants coming from ... in the global advance boilers market., The global ...
(Date:7/13/2014)... Serena Gordon HealthDay Reporter ... new type of sensor for people with diabetes is being ... instead of blood, researchers report. Scientists at Brown University ... using artificial saliva. It uses light, metal and a special ... "Everybody knows that diabetics have to prick their fingers to ...
(Date:7/13/2014)... July 13, 2014 Max International ... Chris Mullin, will be the featured guest at its ... in Puerto Rico. Attendees will learn about Max’s ... in two exhibition basketball games and perform in a ... supplier of health- and energy-boosting supplements , has recently ...
(Date:7/13/2014)... COPENHAGEN, July 13, 2014 A decreased ability ... cognitive impairment and Alzheimer,s disease, while examinations of ... a protein associated with Alzheimer,s, in the brain, ... reported today at the Alzheimer,s Association International Conference ... of the studies, the decreased ability to identify ...
(Date:7/13/2014)... ECS is being founded by ... of a special needs child, I have become keenly ... for contemporary special education resources and evidence-based instruction. Emerald ... and families in the Seattle metro area that are ... education. We welcome the opportunity to serve our community ...
Breaking Medicine News(10 mins):Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 2Health News:North America Advanced Boilers Market is Expected to Reach $518.7billion by 2019 - New Report by MicroMarket Monitor 3Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:New Private School, Emerald City School, Founded in Downtown Seattle Now Accepting 1st to 6th Grade Students Who Learn Differently 2
... Dr. Gunther von Hagens, creator of the BODY ... to present the human saga in its entirety, introduced ... week.(Photo: http://www.newscom.com/cgi-bin/prnh/20090505/CG11117 )With the "HUMAN SAGA" project, ... landscape left uncharted by Andreas Vesalius (1514-1564), the founder ...
... in Traditional Chinese Medicine Research in the Post-genomic Era, ... Medicine (TCM) research, identify problems and propose solutions by ... a forum for the exchange of opinions, experience and ... , The three-year project aims to propose guidelines ...
... Savings Accounts and Supplemental Coverage for Critical Illnesses and ... Guardian Life Insurance Company of America (Guardian), one of ... leading provider of employee benefits for small and mid-sized ... healthcare plan that helps employers and their employees save ...
... YORK, May 5 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: ... improving health through the development, manufacture and,commercialization of a ... today announced that it plans to release first quarter ... market opens. , The Company ...
... don,t make it to the doctor , , TUESDAY, May ... a lack of belief in the importance of vaccinations ... to getting parents to bring their children in for ... linked to children being 2.5 times more likely to ...
... Finder Introduces Initiative to Secure Patient Health InformationNEW YORK, ... of the nation,s healthcare system and said he believes ... five years. The President hopes this will result in ... thousands of new jobs. Todd Feinman, a published security ...
Cached Medicine News:Health News:Dr. Gunther von Hagens 'HUMAN SAGA' Project Presents Sexuality and Reproduction in New Exhibit, The Cycle of Life. 2Health News:King's-led consortium wins €1 million EU funding for Chinese medicine research 2Health News:Guardian Launches Comprehensive, Consumer-Driven Healthcare Program 2Health News:Guardian Launches Comprehensive, Consumer-Driven Healthcare Program 3Health News:Keeping Appointments Key to Keeping Vaccines on Track 2Health News:Obama's Support for Digital Health Records May Increase Identity Theft 2Health News:Obama's Support for Digital Health Records May Increase Identity Theft 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: